Transitioning to aflibercept 8 mg reduces the carbon footprint in ophthalmology, suggesting environmental factors should influence treatment choices.
A transition from conventional aflibercept 2-mg therapy to an aflibercept 8-mg regimen with extended dosing intervals reduces the treatment's carbon footprint by over one-third. These findings support the integration of environmental considerations into therapeutic decisions in ophthalmology, particularly for high-frequency procedures, such as intravitreal injections.
No takes yet. Share an insight, caveat, or question.
Radice et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: